Vator Securities advises Cyxone on 67 MSEK Rights Issue
Cyxone is a Swedish clinical stage medicine platform company focused on developing and advancing novel solutions for patients suffering from severe autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS).
“The proceeds from the Rights Issue will enable us to implement the next important steps in the development of Cyxone’s new treatment for rheumatoid arthritis (RA). We have a solid and well-structured plan for delivering value creation to our shareholders and to patients world-wide, and our experienced team are now looking forward to take the Company to the next level,” comments Tara Heitner, CEO, Cyxone.
Read More
Vator Securities advises Idogen on 50 MSEK Rights Issue
Idogen is a Swedish biotechnology company that develops tolerogenic cell therapies with the aim of treating unwanted activation of the immune system.
The Company conducts three development areas with a focus on treating patients with unwanted activation of the immune system. For the most advanced candidate, IDO 8, intended for patients with severe hemophilia and with antibodies against their treatment, the company’s intention is to submit an application for approval to start a clinical phase I/IIa study in December 2021.
Read More
Vator Securities advises Precise Biometrics on 23 MSEK Directed Share Issue
Precise Biometrics is a global identification software provider, offering products with a range of application for identification in a convenient and secure way. Precise offers products with various applications that enable individuals to identify themselves by using biometrics.
Precise intends to use the net proceeds from the directed issue to finance part of the company’s acquisition of EastCoast Solutions.
Read More
Vator Securities advises SenzaGen on 30 MSEK Directed Share Issue
SenzaGen aims to be a leader in non-animal toxicology testing driving the transition from animal testing to methods better suited to reflect human biology.
The company has a growth strategy which involve continued commercialization of the in house developed GARD® test platform, expansion of the test portfolio with a broader range of tests and pursuing acquisition opportunities of profitable and growing companies with complementary offerings
Read More
Vator Securities advises Sprint Bioscience on 67 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 67,6 million.
Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. Using fragment-based drug discovery, the company develops drug projects in a time- and resource-efficient way. These are then out-licensed to global drug companies during the preclinical phase.
Read More
Vator Securities advises Umecrine Cognition on 35 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 35,1 million.
Umecrine Cognition is developing golexanolone, a drug candidate with a completely new type of mechanism of action targeting the GABAA receptor in the brain.
Read More
Vator Securities advises Plastics Unbound on 30 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 30,3 million.
Plastics Unbound has successfully completed technical and commercial validation through Tier-1 customer trials and production applications and is now transitioning into larger volume orders.
Read More
Vator Swiss Nordic Bio 2022
VATOR SWISS NORDIC BIO 2022 – The Leading Annual European Healthcare Investor Summit in Zürich.
Vator Securities and Business Sweden & partners have the pleasure to invite you to the annual European healthcare investor conference VATOR SWISS NORDIC BIO, connecting fast growing Nordic publicly listed healthcare companies, the most exciting start-ups, and the European investor community
Read More